These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22811448)

  • 1. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.
    Sill MW; Rubinstein L; Litwin S; Yothers G
    Clin Trials; 2012 Aug; 9(4):385-95. PubMed ID: 22811448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated phase II/III clinical trials in oncology: a case study.
    Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
    Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.
    Li Y; Mick R; Heitjan DF
    Clin Trials; 2012 Jun; 9(3):293-302. PubMed ID: 22523304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy.
    DeVeaux M; Kane M; Wei W; Zelterman D
    Pharm Stat; 2019 Nov; 18(6):700-713. PubMed ID: 31507079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting promising treatments in randomized Phase II cancer trials with an active control.
    Cheung YK
    J Biopharm Stat; 2009; 19(3):494-508. PubMed ID: 19384691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring.
    Ray HE; Rai SN
    Pharm Stat; 2012; 11(2):170-6. PubMed ID: 22232063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials.
    Shi H; Yin G
    Stat Methods Med Res; 2018 Jan; 27(1):158-171. PubMed ID: 28034171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.
    Iasonos A; Sabbatini P; Spriggs DR; Aghajanian CA; O'Cearbhaill RE; Hensley ML; Thaler HT
    Int J Gynecol Cancer; 2012 Jan; 22(1):63-9. PubMed ID: 22080877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of Phase II cancer trials evaluating survival probabilities.
    Case LD; Morgan TM
    BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
    Korn EL; Liu PY; Lee SJ; Chapman JA; Niedzwiecki D; Suman VJ; Moon J; Sondak VK; Atkins MB; Eisenhauer EA; Parulekar W; Markovic SN; Saxman S; Kirkwood JM
    J Clin Oncol; 2008 Feb; 26(4):527-34. PubMed ID: 18235113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A predictive probability design for phase II cancer clinical trials.
    Lee JJ; Liu DD
    Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
    Tanaka S; Sakamori Y; Niimi M; Hazama M; Kim YH; Yanagihara K
    Trials; 2011 May; 12():120. PubMed ID: 21569411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.